Vaxart, Inc. (VXRT)

Market Cap	139.14M -17.5%
Revenue (ttm)	148.20M +784.3%
Net Income	-50.70M
EPS	-0.22
Shares Out	239.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	908,070
Average Volume	1,453,731
Open	0.6050
Previous Close	0.6090
Day's Range	0.5210 - 0.6100
52-Week Range	0.2606 - 0.8449
Beta	0.96
RSI	52.75
Earnings Date	Mar 19, 2026

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Steven Lo
• Employees: 105
• Stock Exchange: OTCMKTS
• Ticker Symbol: VXRT

Financial Performance

In 2024, Vaxart's revenue was $28.70 million, an increase of 288.94% compared to the previous year's $7.38 million. Losses were -$66.95 million, -18.82% less than in 2023.